Clinical Trial Search

Primary: Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores — 87.27; 87.33; -1.56; 81.71 score on a scale

Primary: Virological Response (Intention to Treat) — 19; 21; 7; 2 participants

Primary: The Proportion of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 100; 95; 95; 91.2 percentage of subjects

Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants

Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale

Primary: Sustained Virological Response (SVR): Percentage of Participants Who Were HCV Seronegative at 6 Months After Completing Therapy — 59.5; 58.3 percentage of participants

Primary: Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy. — 3 participants

Primary: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase…

Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml

Primary: Sustained Virologic Response (SVR) — 62 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.9; 96.2; 74.1; 100.0 percentage of participants

Primary: Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility — 144; 77; 17; 7 participants

Primary: Number of Participants With Sustained Virologic Response — 70 Participants

Primary: Adverse Event Profile of Repeated Dosing of CF102 — 6; 2; 2; 4 participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment — 100 percentage of participants

Primary: Changes in Interferon Stimulated Genes in the Liver — -0.04915; -0.35948; -0.49980; -0.79328 relative expression

Primary: Number of Subjects Who Achieve Sustained Viral Response (SVR12) 12 Weeks After the Stop of Treatment Drugs — 516 Participants

Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants

Primary: Change in Hepatitis C Virus RNA Levels During Phase I — 0.50; 0.70 log(IU/mL) — p=0.54

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment — 96.4 percentage of participants

Primary: Sustained Virologic Response — 24; 25 participants

Primary: Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment — -0.05 ng/g

Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001

Primary: Number of Participants Linked to Care — 8; 16 Participants — p=0.036

Primary: Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B) — 48.8; 39.5 percentage of participants — p=0.510

Primary: Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Domain at End of Treatment (EOT) — -3.2; -3.0; -7.4; -1.2 units on a scale — p=0.647

Primary: Number of Participants With Sustained Virologic Response (SVR) — 11; 11 participants

Primary: Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT) — 13.65 Percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.1; 96.3; 100; 100 percentage of participants